NOVARTIS-LPT109096



Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer
lapatinib
LPT109096
NCT00524303
Cancer, Breast
Phase 2
 
The raw dataset is included within the analysis-ready dataset.
November 2016